How Viable Is The Future Of The “Traditional” CGM?
Executive Summary
Flagship products like Dexcom’s G7 and Abbott’s FreeStyle Libre 3 offer currently unrivalled accuracy of blood glucose measurement. However, as truly noninvasive technologies improve, the future basis for these companies’ growth is on shaky ground.
You may also be interested in...
Ladies! Meet Movano: The Fashion-Forward Smart Ring Backed By Medical-Grade Accuracy
Movano expects to introduce its first smart ring, this one specifically for women, in the first half of 2023 in the US while it continues clinical trials to add medical parameters requiring FDA clearances, such as glucose and blood pressure.
Exec Chat: Dexcom Continues To Evolve Blood Glucose Measurement Market
In an interview with Medtech Insight, Dexcom CEO Kevin Sayer discussed his views on the blood glucose measurement market, how he thinks it will change, and Dexcom’s responsibilities to patients, regulators and payors.
Moving Pharma Execs Out Of The Shadows Is Key To Building Public Trust
2024 Rising Leader, Jack O’Meara, says the industry must ‘promote personalities’ when building new biotech businesses to gain the trust of investors and the public.